{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:10:11Z","timestamp":1789089011149,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,14]],"date-time":"2027-08-14T00:00:00Z","timestamp":1818201600000},"content-version":"am","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr Miriam & Sheldon G Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016947","name":"Swim Across America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.medj.2026.101231","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:40:38Z","timestamp":1785336038000},"page":"101231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanoma"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8530-0907","authenticated-orcid":false,"given":"Lilit","family":"Karapetyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Kalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Schachner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Kuriakose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MacLean S.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl A.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayah N.","family":"Al-Bzour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Falahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Mullinax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vernon K.","family":"Sondak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth Y.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane L.","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Moran-Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neale","family":"Lopez-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony E.","family":"Alleyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan V.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Schell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Brohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Eroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad A.","family":"Tarhini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil I.","family":"Khushalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Mul\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amod A.","family":"Sarnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Beatty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Pilon-Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101231_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.medj.2026.101231_bib2","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101231_bib3","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101231_bib4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","article-title":"Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2","volume":"271","author":"Rosenberg","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2026.101231_bib5","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.medj.2026.101231_bib6","doi-asserted-by":"crossref","first-page":"290.e1","DOI":"10.1016\/j.jtct.2025.12.009","article-title":"Safety and efficacy of tumor-infiltrating lymphocyte (TIL) therapy with reduced-dose lymphodepleting conditioning in high-risk metastatic melanoma patients","volume":"32","author":"Karapetyan","year":"2026","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.medj.2026.101231_bib7","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1200\/JCO-25-00765","article-title":"Long-term Efficacy and Safety of Lifileucel Tumor-infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Melanoma: A 5-year Analysis of the C-144-01 Study","volume":"43","author":"Medina","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101231_bib8","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101231_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008640","article-title":"Biomarkers for response to TIL therapy: a comprehensive review","volume":"12","author":"Albarr\u00e1n Fern\u00e1ndez","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.medj.2026.101231_bib10","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1158\/1078-0432.CCR-17-3649","article-title":"Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome","volume":"24","author":"Forget","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2026.101231_bib11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1158\/1078-0432.CCR-14-1934","article-title":"Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy","volume":"21","author":"Chacon","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2026.101231_bib12","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1126\/science.abb9847","article-title":"Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer","volume":"370","author":"Krishna","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.medj.2026.101231_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150535","article-title":"Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma","volume":"132","author":"Kristensen","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.medj.2026.101231_bib14","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/CJI.0b013e31826e8f5f","article-title":"Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma","volume":"35","author":"Pilon-Thomas","year":"2012","journal-title":"J. Immunother."},{"key":"10.1016\/j.medj.2026.101231_bib15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3389\/fonc.2018.00044","article-title":"Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma","volume":"8","author":"Mullinax","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.medj.2026.101231_bib16","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1158\/1078-0432.CCR-22-2103","article-title":"Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma","volume":"28","author":"Hall","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2026.101231_bib17","doi-asserted-by":"crossref","DOI":"10.1186\/2051-1426-3-S2-P49","article-title":"Clinical results of combined vemurafenib and tumor-infiltrating lymphocyte therapy for metastatic melanoma","volume":"3","author":"Sarnaik","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.medj.2026.101231_bib29","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","article-title":"Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma","volume":"8","author":"Lauss","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2026.101231_bib18","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","article-title":"Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations","volume":"24","author":"Kugel","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2026.101231_bib19","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1158\/1078-0432.CCR-10-2769","article-title":"Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy","volume":"17","author":"Joseph","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2026.101231_bib20","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41577-021-00646-4","article-title":"Immune ageing at single-cell resolution","volume":"22","author":"Mogilenko","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.medj.2026.101231_bib21","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1158\/1078-0432.CCR-21-2390","article-title":"Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy","volume":"28","author":"Andrews","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2026.101231_bib22","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","article-title":"Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8(+) T cells to promote antitumor immunity","volume":"187","author":"Cillo","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.medj.2026.101231_bib23","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CJI.0000000000000124","article-title":"Metastatic Lung Lesions as a Preferred Resection Site for Immunotherapy With Tumor Infiltrating Lymphocytes","volume":"39","author":"Ben-Avi","year":"2016","journal-title":"J. Immunother."},{"key":"10.1016\/j.medj.2026.101231_bib24","doi-asserted-by":"crossref","first-page":"5289","DOI":"10.1158\/1078-0432.CCR-21-1171","article-title":"Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma","volume":"27","author":"Seitter","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2026.101231_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znaf090","article-title":"Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial","volume":"112","author":"Tas","year":"2025","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.medj.2026.101231_bib26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","article-title":"B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome","volume":"19","author":"Fridman","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101231_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009231","article-title":"Differences in the pathological, transcriptomic, and prognostic implications of lymphoid structures between primary and metastatic cutaneous melanomas","volume":"12","author":"Karapetyan","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.medj.2026.101231_bib28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/srep00765","article-title":"12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?","volume":"2","author":"Messina","year":"2012","journal-title":"Sci. Rep."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026002345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026002345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:49:52Z","timestamp":1789087792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634026002345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666634026002345"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101231","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanoma","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101231","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101231"}}